248
Views
0
CrossRef citations to date
0
Altmetric
Appendix

Erratum

Page 731 | Published online: 04 Nov 2011
This article refers to:
Emerging drugs for hepatocellular carcinoma

Expert Opinion on Emerging Drugs wishes to inform its readers of the following incident of redundant publication.

The following publication:

Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma Expert Opin Emerg Drugs 2006 Sep;11(3):469-87 Citation[1] contains information reported also in the previously published article, Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25(2):212-25 Citation[2], without adequately referencing the prior publication.

Although Roberts and Gores Citation[1] report considerable additional information not contained in Citation[2], Expert Opinion on Emerging Drugs regrets that the earlier publication was not adequately referenced. The editors of Expert Opinion on Emerging Drugs were not fully apprised by the authors of the prior publication and discovered the modest overlap only after it was highlighted to the editors after publication.

Bibliography

  • Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006;11(4):469-87
  • Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25(2):212-25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.